Comparative Pharmacology
Head-to-head clinical analysis: HYTONE versus TOPICORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYTONE versus TOPICORT.
HYTONE vs TOPICORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone (topical) binds to glucocorticoid receptors, activating anti-inflammatory proteins and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Topical: Apply cream or ointment to affected area 2-4 times daily. Limit treatment area to less than 50% of body surface area. Maximum duration: 2 weeks unless directed by physician.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
None Documented
None Documented
30–60 minutes (terminal elimination half-life; short duration requires frequent dosing)
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
Renal (primarily as metabolites; ~25% as unchanged drug) and biliary/fecal
Renal (metabolites): ~75%; Fecal: ~25%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid